摘要目的：评价 XELOX方案和 FOLFOX方案治疗晚期结直肠癌的临床疗效和不良反应。方法计算机检索万方数据库、维普数据库、CNKI数据库和PubMed数据库上公开发表的XELOX方案和FOLFOX方案治疗大肠癌的随机对照试验,并进行筛选,提取实验设计、研究对象特征、干预措施和研究结果,采用 ReMan 5.3软件进行统计分析。结果共纳入18篇合格文献,Meta分析结果提示 XELOX组有效率为43.50%(311/715),与 FOLFOX组有效率47.37%(351/741)比较,两组总有效率差异无统计学意义[OR =0.87,95%CI(0.71,1.07),P =0.19]。白细胞减少两组比较差异有统计学意义[OR =0.41,95%CI(0.29,0.58),P <0.001]。两组恶心和呕吐情况比较差异无统计学意义[OR=0.86,95%CI(0.74,1.01),P =0.07]。两组腹泻比较差异无统计学意义[OR =1.05,95%CI(0.82,1.35),P =0.68]。两组口腔黏膜炎比较差异无统计学意义[OR =0.84,95%CI(0.52,1.34),P=0.01]。两组神经毒性比较差异有统计学意义[OR =0.89,95%CI(0.85,0.93),P<0.00001]。两组手足综合征比较差异有统计学意义[OR =3.77,95%CI(2.29,6.21),P<0.001]。结论 XELOX方案治疗晚期结直肠癌的疗效和 FOLFOX方案近期疗效相当,在白细胞减少和神经毒性上 XELOX组较 FOLFOX组低,在手足综合征上 XELOX组较高,在经济学指标上有一定优势。difference in comparison of hand-foot syndrome incidence between the two protocols [OR =3.77,95%CI (2.29,6.21),P<0.001]. Conclusion The efficacy of XELOX protocol for patient with colorectal cancer was equivalent to FOLFOX protocol,but it had some advantages in lower leukopenia,neurotoxicity and econo-my and disadvantage in higher hand-foot syndrome.